Yazan Al Homsi: The Vancouver Investor Bridging East and West

Yazan Al Homsi has built a distinctive presence in North American venture capital from his base in Vancouver — one grounded in a personal story that spans continents and in an investment philosophy shaped by exposure to genuinely different economic contexts. Born in Saudi Arabia and now firmly established in British Columbia, Al Homsi brings […]

Read More

The Long-Hold Strategy: How 3G Capital Redefines Ownership

Private equity has long been associated with a particular rhythm: acquire, improve, exit. 3G Capital has challenged this rhythm at every step. The New York-based firm’s long-hold strategy represents a fundamental departure from the conventional buyout model—one that prioritizes compound value creation over rapid return of capital, and genuine business building over the financial optimization […]

Read More

JP Conte on Why First-Generation College Students Face Higher Dropout Risk After Poor Grades

When a college student receives a failing grade or a GPA that falls below expectations, the emotional and practical consequences can vary dramatically depending on their background. For first-generation college students — those whose parents did not earn a four-year degree — the psychological fallout from poor academic performance is often more severe and more […]

Read More

Michael Gold’s Westport Firm Targets an Overlooked Wealth Tier Between the mass-market wealth platforms serving millions of households and the exclusive family offices built for billionaires

Michael Gold believes has been largely overlooked. His firm, Gold Family Wealth, based in Westport, Connecticut, was built specifically to serve that middle group. Gold Family Wealth focuses on households with $20 million to $150 million in net worth. Michael Gold, the firm’s founder and CEO, argues these families face nearly the same complexity as […]

Armistice Capital’s 13F Filings Document Concentrated Institutional Activity in Specialty Pharma

Armistice Capital appears in the 13F filings of multiple specialty pharmaceutical companies, reflecting a portfolio strategy concentrated on drug developers with active regulatory pipelines across rare diseases, neurological conditions, and cardiovascular medicine. The fund manages more than $7 billion in assets and ranks among the more active healthcare-focused hedge funds tracked in institutional holdings databases. […]